Integrated Biopharma Stock Price To Sales
Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. The fundamental analysis module provides a way to measure Integrated Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock.
Integrated |
Integrated Biopharma OTC Stock Price To Sales Analysis
Integrated Biopharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Integrated Biopharma Price To Sales | 0.21 X |
Most of Integrated Biopharma's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Integrated Biopharma has a Price To Sales of 0.2067 times. This is 91.49% lower than that of the Personal Products sector and 98.22% lower than that of the Consumer Staples industry. The price to sales for all United States stocks is 98.19% higher than that of the company.
Integrated Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in price to sales category among its peers.
Integrated Fundamentals
Return On Equity | 0.13 | ||||
Return On Asset | 0.0336 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | 0.03 % | ||||
Current Valuation | 12.05 M | ||||
Shares Outstanding | 29.95 M | ||||
Shares Owned By Insiders | 68.58 % | ||||
Shares Owned By Institutions | 0.06 % | ||||
Price To Earning | 2.52 X | ||||
Price To Book | 0.56 X | ||||
Price To Sales | 0.21 X | ||||
Revenue | 56.25 M | ||||
Gross Profit | 6.55 M | ||||
EBITDA | 3.54 M | ||||
Net Income | 3.84 M | ||||
Cash And Equivalents | 343 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 53 K | ||||
Debt To Equity | 0.11 % | ||||
Current Ratio | 3.16 X | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | 4.09 M | ||||
Earnings Per Share | 0.11 X | ||||
Number Of Employees | 147 | ||||
Beta | 0.52 | ||||
Market Capitalization | 11.2 M | ||||
Total Asset | 25.25 M | ||||
Retained Earnings | (59.89 M) | ||||
Working Capital | 913 K | ||||
Current Asset | 12.7 M | ||||
Current Liabilities | 11.79 M | ||||
Net Asset | 25.25 M |
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ONEOK could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ONEOK when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ONEOK - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ONEOK Inc to buy it.
The correlation of ONEOK is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ONEOK moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ONEOK Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ONEOK can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |